Striatal D1- and D2-dopamine receptor sites are separately detectable in vivo

We have characterized in particulate fractions of normal rat striatum the in vivo binding kinetics, binding affinity, and pharmacological profiles of [3H]SCH 23390, a ligand selective for the D1-subtype of dopamine (DA) receptor, and compared these to [3H]spiperone, a ligand classically associated with the D2 DA receptor subtype. The pharmacological specificity of each ligand's in vivo binding is very similar to binding to striatal homogenates in vitro. While similar maximum numbers (Bmax) of striatal binding sites exist in vivo compared to in vitro for both ligands, binding affinities in vivo for both ligands are reduced 125- to 200-fold compared to in vitro. In vivo binding of [3H]SCH 23390 to striatum is not increased by dopamine denervation produced by 6-hydroxydopamine lesions of the nigrostriatal pathway. In vivo binding of [3H]SCH 23390 and [3H]spiperone to striatum is not significantly reduced by increased synaptic concentration of dopamine following D-amphetamine administration. 125I-SCH 23982, the iodinated analogue of SCH 23390, localizes very highly to dopaminergic forebrain areas following i.v. administration. External imaging of mammalian and human brain D1-receptors is potentially feasible with this ligand.